28 related articles for article (PubMed ID: 1361436)
1. Comparative immunohistochemical studies of p53 and proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions in pancreatic duct cell carcinomas.
Suzuki T; Takano Y
Jpn J Cancer Res; 1993 Oct; 84(10):1072-7. PubMed ID: 7901190
[TBL] [Abstract][Full Text] [Related]
2. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma.
Toma V; Hauri D; Schmid U; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Gasser TC; Sauter G; Roth J
Am J Pathol; 1999 Nov; 155(5):1427-32. PubMed ID: 10550296
[TBL] [Abstract][Full Text] [Related]
3. Lead article: The prognostic significance of proliferating cell nuclear antigen (pcna) in laryngeal cancer.
Sapci T; Filizel F; Karavus A; Akbulut UG; Karavus M
Indian J Otolaryngol Head Neck Surg; 1998 Oct; 50(4):354-61. PubMed ID: 23119458
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma.
Müller W; Schneiders A; Meier S; Hommel G; Gabbert HE
Br J Cancer; 1996 Sep; 74(5):759-65. PubMed ID: 8795579
[TBL] [Abstract][Full Text] [Related]
5. Cell proliferation indices, morphometry and DNA flow cytometry provide objective criteria for distinguishing low and high grade bladder carcinomas.
Pich A; Chiusa L; Comino A; Navone R
Virchows Arch; 1994; 424(2):143-8. PubMed ID: 7910097
[TBL] [Abstract][Full Text] [Related]
6. Proliferating cell nuclear antigen (PCNA) expression in regenerating rat liver after partial hepatectomy.
Theocharis SE; Skopelitou AS; Margeli AP; Pavlaki KJ; Kittas C
Dig Dis Sci; 1994 Feb; 39(2):245-52. PubMed ID: 7906221
[TBL] [Abstract][Full Text] [Related]
7. Nucleolar and argyrophilic nucleolar organizer region counts in urothelial carcinomas with special emphasis on grade II tumors.
Helpap B; Loesevitz L; Bulatko A
Virchows Arch; 1994; 425(3):265-9. PubMed ID: 7812512
[TBL] [Abstract][Full Text] [Related]
8. Standardized AgNOR analysis: its usefulness in surgical oncology.
Ofner D; Schmid KW
Histochem Cell Biol; 1996 Aug; 106(2):193-6. PubMed ID: 8877379
[TBL] [Abstract][Full Text] [Related]
9. In situ standardised AgNOR analysis: a simplified method for routine use to determine prognosis and chemotherapy efficiency in colorectal adenocarcinoma.
Ofner D
Micron; 2000 Apr; 31(2):161-4. PubMed ID: 10588062
[TBL] [Abstract][Full Text] [Related]
10. Comparative assessment of proliferating cell nuclear antigen immunostaining and of nucleolar organizer region staining in transitional cell carcinomas of the urinary bladder. Correlation with other conventional prognostic pathologic parameters.
Skopelitou A; Korkolopoulou P; Papanicolaou A; Christodoulou P; Thomas-Tsagli E; Pavlakis K
Eur Urol; 1992; 22(3):235-40. PubMed ID: 1361436
[TBL] [Abstract][Full Text] [Related]
11. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis.
Pich A; Chiusa L; Margaria E
Cancer Detect Prev; 1995; 19(3):282-91. PubMed ID: 7750118
[TBL] [Abstract][Full Text] [Related]
12. Proliferating cell nuclear antigen and nucleolar organizer regions in CNS tumors: correlation with histological type and tumor grade. A comparative study of 82 cases on paraffin sections.
Korkolopoulou P; Christodoulou P; Papanikolaou A; Thomas-Tsagli E
Am J Surg Pathol; 1993 Sep; 17(9):912-9. PubMed ID: 8102513
[TBL] [Abstract][Full Text] [Related]
13. Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas.
Krüger S; Müller H
Br J Urol; 1995 Apr; 75(4):480-4. PubMed ID: 7788260
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of proliferating cell nuclear antigen, Ki-67 and nucleolar organizer region in transitional cell carcinoma of the bladder.
Bozlu M; Orhan D; Baltaci S; Yaman O; Elhan AH; Tulunay O; Müftüoğlu YZ
Int Urol Nephrol; 2002; 33(1):59-66. PubMed ID: 12090340
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
